|Bid||76.30 x 1400|
|Ask||76.33 x 1000|
|Day's Range||75.58 - 77.53|
|52 Week Range||64.80 - 102.43|
|Beta (5Y Monthly)||0.59|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2020 - Mar 2, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||89.57|
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
LivaNova PLC today announced it will present new registry data on VNS Therapy at the American Epilepsy Society 2019 Annual Meeting.
LivaNova Plc said on Wednesday it would stop developing its minimally-invasive mitral heart valve device and restructure its heart valve unit after years of declining sales. The company is racing with firms such as Medtronic Plc to launch the first transcatheter mitral valve replacement (TMVR) device that can help patients avoid traditional open-heart surgeries through the use of a catheter or tube to replace the valve. The UK-based company said the restructuring of its heart valve business, which brought in nearly $130 million in 2018 sales or about 11% of total revenue, could impact about 150 employees in three of its plants and would also eliminate operational overlap.
LivaNova PLC (LIVN), a market-leading medical technology and innovation company, today announced it is ending its Caisson Transcatheter Mitral Valve Replacement (TMVR) program and will undertake a restructuring of its heart valve business to improve profitability and ensure business continuity. The LivaNova heart valve business line represented nearly $130 million in revenue for full-year 2018 and has experienced a revenue decline over the last five years across both biological and mechanical valves.
LivaNova PLC (LIVN), a market-leading medical technology company, today announced Thad Huston, Chief Financial Officer, will participate in discussions at the Berenberg European Conference 2019 in London and at the Piper Jaffray 31st Annual Healthcare Conference in New York. The discussion at the Berenberg conference is scheduled to begin at 9:45 a.m. Greenwich Mean Time on Tuesday, Dec. 3, and the discussion at the Piper Jaffray conference is scheduled to begin at 8:30 a.m. Eastern Time on Thursday, Dec. 5.
The company is working to bring more awareness to epilepsy, the fourth most common neurological disorder impacting more than 65 million people of all ages around the world. As that number continues to rise, there is an increasing need to bring attention to the disorder, share information regarding available treatment options and increase education to break down the stigma associated with epilepsy. LivaNova has strong partnerships throughout the epilepsy community.
LivaNova (LIVN) delivered earnings and revenue surprises of 16.67% and -1.55%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have driven the performance of the players in the medical products space this earnings season.
Is LivaNova PLC (NASDAQ:LIVN) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. […]
LivaNova PLC , a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present at the Stifel 2019 Healthcare Conference on Wednesday, November 20 in New York at 3 p.m.
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LivaNova PLC (LIVN), a market-leading medical technology and innovation company, today announced the publication of a new study in Neurology, which suggests that chronic epilepsy may be associated with key measures of sudden cardiac death risk.1 This is the third in a series of studies1-3 to evaluate cardiac electrical instability in patients with chronic epilepsy but the first to compare the cardiac impact of the disease among patients with chronic epilepsy to those who are newly diagnosed. The study in Neurology evaluated established markers of sudden cardiac death risk, T-wave alternans (TWA) and heart rate variability (HRV), in patients with chronic epilepsy compared to patients with newly diagnosed epilepsy.
LivaNova PLC (LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its third quarter 2019 results on Wednesday, October 30, 2019 at 12 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its third quarter 2019 results prior to the call. LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world.
LivaNova (LIVN) delivered earnings and revenue surprises of 2.94% and 1.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?